$8.24
-0.33-3.85%
Last update: Nov 5, 1:01 AM
BioCryst Pharmaceuticals Inc
BCRXNASDAQ
The average analyst price target for BioCryst Pharma is $20.71, 150.7% above the current price. Of 12 analysts, 10 rate it Buy and 2 Hold. Targets range from $9 to $32. The latest change came on Sep 30, 2026, when JP Morgan raised its price target on BioCryst Pharma from $12 to $13 and kept a Neutral rating.
Price Target Range — 12 Quarters
Analyst Consensus — 12 Analysts
Rating Trend — Last 9 Months
